Efficacy and safety comparison of insulin detemir plus insulin aspart versus insulin glargine plus insulin aspart in type 2 diabetes.
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Insulin detemir (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms NOVEL-2
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 10 May 2011 Last checked against European Clinical Trials Database record.
- 07 Jul 2009 Actual patient number changed from 319 to 324 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History